Nuformix extends its partnership with Onyx-IPCA

Cambridge, UK - 30th November 2016

Following on from Nuformix’s existing cocrystal discovery and development pact with Onyx-IPCA, Nuformix is pleased to announce it has extended its agreement to commence process development activities that will facilitate GMP production of its proprietary drug forms.

Nuformix Chief Executive Officer, Dr Dan Gooding, said: “We’d struggle to have found a better partnership than that which we have built with Onyx-IPCA. Their unique understanding of our technology and assets, combined with their proven expertise in process scale-up and GMP supply, positions Onyx perfectly to deliver our GMP material as we prepare to commence clinical activities for our lead programmes.”